UY31669A1 - "formulación farmacéutica que comprende oxabispidinas /236" - Google Patents

"formulación farmacéutica que comprende oxabispidinas /236"

Info

Publication number
UY31669A1
UY31669A1 UY031669A UY31669A UY31669A1 UY 31669 A1 UY31669 A1 UY 31669A1 UY 031669 A UY031669 A UY 031669A UY 31669 A UY31669 A UY 31669A UY 31669 A1 UY31669 A1 UY 31669A1
Authority
UY
Uruguay
Prior art keywords
oxabispidins
pharmaceutical formulation
pharmaceutically acceptable
oxabispidines
prevention
Prior art date
Application number
UY031669A
Other languages
English (en)
Inventor
Kristina Roos
Hans Joensson
Hans Carlsson
Anders R Berggren
Erik Snderlind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31669A1 publication Critical patent/UY31669A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación farmacéutica de liberación modificada que comprende oxabispidinas como ingrediente activo, o una sal farmacéuticamente aceptable del mismo; y un diluyente o vehículo farmacéuticamente aceptable, para ser utilizado en el tratamiento o prevención de las arritmias cardíacas.
UY031669A 2008-02-22 2009-02-20 "formulación farmacéutica que comprende oxabispidinas /236" UY31669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3064308P 2008-02-22 2008-02-22

Publications (1)

Publication Number Publication Date
UY31669A1 true UY31669A1 (es) 2009-09-30

Family

ID=40985767

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031669A UY31669A1 (es) 2008-02-22 2009-02-20 "formulación farmacéutica que comprende oxabispidinas /236"

Country Status (5)

Country Link
AR (1) AR070617A1 (es)
PE (1) PE20091464A1 (es)
TW (1) TW200940110A (es)
UY (1) UY31669A1 (es)
WO (1) WO2009105023A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586809A (zh) * 2015-01-08 2015-05-06 浙江亚太药业股份有限公司 一种埃索美拉唑镁微丸肠溶片及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2006135316A1 (en) * 2005-06-13 2006-12-21 Astrazeneca Ab New oxabispidine compounds for the treatment of cardiac arrhythmias
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
EP2018157A2 (en) * 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs

Also Published As

Publication number Publication date
AR070617A1 (es) 2010-04-21
TW200940110A (en) 2009-10-01
WO2009105023A1 (en) 2009-08-27
PE20091464A1 (es) 2009-10-24

Similar Documents

Publication Publication Date Title
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MD4577C1 (ro) Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
AR114032A2 (es) 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma
ECSP11011199A (es) Formulación de depósito de octreotida con niveles de exposición constantemente altos
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
AR106351A1 (es) Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
UY31669A1 (es) "formulación farmacéutica que comprende oxabispidinas /236"
ECSP12012352A (es) Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20121218